The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
ORKA filed a notice of proposed sale of 35,000 shares of Common Stock. The filing identifies Morgan Stanley Smith Barney LLC as the broker and lists a 02/14/2024 partnership distribution of 35,000 shares for cash. The excerpt also records a prior 10b5-1 sale by Carl Dambkowski of 105,000 shares on 05/21/2026 for $6,191,367.00.
Oruka Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 2, 2026. Stockholders elected two Class II directors, Lawrence Klein and Chris Martin, to serve until the 2029 annual meeting. Klein received 43,918,579 shares voted for and 63,593 withheld, while Martin received 43,936,173 shares for and 45,999 withheld, with 1,267,194 broker non-votes.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, with 45,206,297 shares for, 39,637 against, and 3,432 abstaining. In a non-binding advisory vote, stockholders approved the compensation of named executive officers, with 43,033,967 shares for, 875,114 against, 73,091 abstaining, and 1,267,194 broker non-votes.
Oruka Therapeutics director Carl Dambkowski received a grant of 9,136 stock options on Common Stock. These options have an exercise price of $55.23 per share and expire on June 1, 2036. The grant was a compensation-related award, bringing his directly held stock options to 9,136. According to the vesting terms, the option vests as to 1/12 of the underlying shares monthly beginning on June 2, 2026, so the award becomes exercisable gradually over time rather than immediately.
Oruka Therapeutics, Inc. director Samarth Kulkarni received a grant of options covering 9,136 shares of common stock. The options have an exercise price of $55.23 per share and expire on June 1, 2036. According to the footnote, the award vests in equal monthly installments over 12 months starting June 2, 2026.
Oruka Therapeutics director Martin Christopher Nathan received a grant of stock options for 9,136 shares of common stock. These options have an exercise price of $55.23 per share and expire on June 1, 2036. The award vests in equal monthly installments over 12 months starting June 2, 2026, aligning the director’s compensation with future company performance.
BALL KRISTINE M reported acquisition or exercise transactions in this Form 4 filing.
Oruka Therapeutics director Kristine M. Ball received a grant of stock options covering 9,136 shares of common stock at 55.23 per share. The options vest in 12 equal monthly installments beginning on June 2, 2026 and expire on June 1, 2036. Following this award, she holds options for 9,136 shares directly.
Oruka Therapeutics, Inc. reported that investment vehicles managed by Fairmount Funds Management received a new stock option grant linked to its common stock. The option covers 9,136 shares with an exercise price of $55.23 per share and expires on June 1, 2036.
The option vests in equal monthly installments of 1/12 starting on June 2, 2026, contingent on continued service to Oruka Therapeutics. The filing explains that Peter Harwin holds the option for one or more Fairmount-managed funds and must deliver any net cash or stock from the option to Fairmount for those funds’ benefit.
Fairmount, Harwin, and Tomas Kiselak each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. The transaction is characterized as a grant or award acquisition of a derivative security, rather than an open-market trade.
Oruka Therapeutics, Inc. entered into a First Amendment to its IL-23 License Agreement with Paragon Therapeutics, Inc. This amendment broadens Oruka’s licensed field to cover all therapeutic, prophylactic, palliative and diagnostic uses of the IL‑23 program, including inflammatory bowel disease, subject to timing limits on when dosing may begin.
Under the amendment, Oruka may not dose a human patient in a clinical trial of ORKA‑001 for inflammatory bowel disease in a combination regimen until June 1, 2028, or as a monotherapy until June 1, 2030. If Oruka or a Paragon licensee completes a material transaction such as a change of control, any remaining restrictions outside the original field will continue only until June 1, 2028 and then terminate.
Oruka Therapeutics director Carl Dambkowski reported a mix of stock sales and option exercises in Oruka Therapeutics, Inc. common stock. On May 21, 2026, he sold a total of 105,000 shares in open‑market transactions at weighted average prices around $58–$60 per share under a pre‑arranged Rule 10b5‑1 trading plan. On the same date, he exercised stock options and warrants covering 62,260 shares at exercise prices of $6.84, $7.80, and $11.77 per share, converting derivative awards into common stock. He continues to hold unexercised options and warrants that expire between 2034 and 2035.
ORKA-related securities holder submitted a Form 144 proposing sales of common stock totaling 105,000 shares. The filing lists two transactions: 62,260 shares tied to an Exercise of Stock Options dated 05/21/2026 and 42,740 shares from a Partnership Distribution dated 02/14/2024. The sales are described as cash transactions.